Open AccessPerioperative bevacizumab improves survival following lung metastasectomy for colorectal cancer in patients harbouringv-Ki-ras2 Kirsten rat sarcoma viral oncogene homologueexon 2 codon 12 mutations†
Author(s) -
Stéphane Renaud,
Mickaël Schaeffer,
PierreEmmanuel Falcoz,
Joseph Seitlinger,
B. Romain,
AnneClaire Voegeli,
M Legrain,
Jérémie Reeb,
Nicola Santelmo,
S. Rohr,
Cécile Brigand,
Anne Olland,
Dominique Guénot,
Gilbert Massard
Publication year - 2016
Publication title -
european journal of cardio-thoracic surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 133
eISSN - 1873-734X
pISSN - 1010-7940
DOI - 10.1093/ejcts/ezw304
Subject(s) - metastasectomy , medicine , kras , colorectal cancer , bevacizumab , oncology , perioperative , chemotherapy , sarcoma , neoadjuvant therapy , gastroenterology , cancer , surgery , pathology , breast cancer
The role of perioperative chemotherapy (POC) and targeted therapies in lung metastasectomy for colorectal cancer (CRC) is still subject to debate. We aimed to evaluate whether POC and targeted therapies were associated with different outcomes according to the mutational status.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom